See more : Fineland Living Services Group Limited (9978.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Tryp Therapeutics Inc. (TRYPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tryp Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- XS Financial Inc. (XSHLF) Income Statement Analysis – Financial Results
- Sembcorp Industries Ltd (U96.SI) Income Statement Analysis – Financial Results
- M. K. Proteins Limited (MKPL.BO) Income Statement Analysis – Financial Results
- Lionco Pharmaceutical Group Co.,Ltd. (603669.SS) Income Statement Analysis – Financial Results
- Aequi Acquisition Corp. (ARBGW) Income Statement Analysis – Financial Results
Tryp Therapeutics Inc. (TRYPF)
About Tryp Therapeutics Inc.
Tryp Therapeutics Inc., a pharmaceutical company, focuses on identifying and developing compounds for diseases with high unmet medical needs. The company's lead development program is (PFN), which is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. Its PFN program candidates include TRP-8802 and TRP-8803 for fibromyalgia, phantom limb pain, binge eating disorder, complex regional pain syndrome, and hypothalamic obesity. The company has an agreement with the Calvert Labs to design and execute exploratory studies related to psilocybin-for-neuropsychiatric disorders program; and a service agreement with Fluence to provide design and training for the psychotherapeutic portion of Tryp's clinical trial activities. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. The company was incorporated in 2019 and is based in Kelowna, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.36M | 2.96M | 889.98K | 8.33K |
| General & Administrative | 2.37M | 4.40M | 4.41M | 386.62K |
| Selling & Marketing | 0.00 | 0.00 | 1.98M | 27.67K |
| SG&A | 2.37M | 4.40M | 6.40M | 414.29K |
| Other Expenses | -522.25K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.72M | 7.36M | 7.29M | 422.62K |
| Cost & Expenses | 4.72M | 7.36M | 7.29M | 422.62K |
| Interest Income | 1.75K | 3.25K | 10.93K | 0.00 |
| Interest Expense | 522.24K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | 228.49K | 236.56K | 206.30K |
| EBITDA | -4.70M | -7.23M | -6.31M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -4.70M | -7.23M | -6.31M | -422.62K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -542.91K | -265.05K | -966.61K | 0.00 |
| Income Before Tax | -5.27M | -7.49M | -8.25M | -422.62K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 538.19K | 123.54K | 959.32K | -458.04 |
| Net Income | -5.27M | -7.49M | -8.25M | -422.62K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.05 | -0.10 | -0.12 | -0.01 |
| EPS Diluted | -0.05 | -0.10 | -0.12 | -0.01 |
| Weighted Avg Shares Out | 96.42M | 78.06M | 66.67M | 38.39M |
| Weighted Avg Shares Out (Dil) | 96.42M | 78.06M | 66.67M | 38.39M |
Tryp Therapeutics Files Amended Financial Statements for the Six Months Ended February 29, 2024
Tryp Therapeutics and Exopharm Limited Announce Completion of Plan of Arrangement
CSE Bulletin: Delist - Tryp Therapeutics Inc. (TRYP)
Tryp Therapeutics Provides Update on Plan of Arrangement With Exopharm Limited and Announces Voluntary Trading Halt
Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order
CSE Bulletin: Reinstatement - Tryp Therapeutics Inc. (TRYP)
Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting
Tryp Therapeutics and Exopharm Limited Secure Pivotal 2 Cent Waiver From ASX
Tryp Therapeutics Announces Significant Milestone in Its Clinical Trial Program for Trp-8803 (IV-infused Psilocin)
Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan
Source: https://incomestatements.info
Category: Stock Reports